Developed by Ascentage Pharma, lisaftoclax is an orally available Bcl-2 inhibitor. Early data from the studies have demonstrated effects on hematologic malignancies and solid tumors. Lisaftoclax is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback